Regulatory aspects of integration of pharmacogenetics into drug development

被引：0
|
作者：
Shah R.R. [1 ]
机构：
[1] Pharmacogenetics Working party, Regulatory Sub-group
来源：
International Journal of Pharmaceutical Medicine | 2001年 / 15卷 / 2期
关键词：
Debrisoquine; Narrow Therapeutic Index; CYP2D6 Activity; Drug Development Programme; Metabolic Elimination;
D O I：
10.1097/00124363-200104000-00007
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：67 / 69
页数：2
相关论文
共 50 条
  • [31] Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress
    Po, ALW
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (01) : 1 - 4
  • [32] Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
    Miriam G. Mooij
    Anne T. Nies
    Catherijne A. J. Knibbe
    Elke Schaeffeler
    Dick Tibboel
    Matthias Schwab
    Saskia N. de Wildt
    Clinical Pharmacokinetics, 2016, 55 : 507 - 524
  • [33] Pharmacogenetics: pharmacogenie or pharmacogenerality in future drug discovery and development?
    Anthony D. Dayan
    International Journal of Pharmaceutical Medicine, 2001, 15 (2) : 54 - 56
  • [34] Opportunities and strategies for introducing pharmacogenetics into early drug development
    Chamberlain, JC
    Joubert, PH
    DRUG DISCOVERY TODAY, 2001, 6 (11) : 569 - 574
  • [35] Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects
    Mann, M. W.
    Pons, G.
    NEUROCHIRURGIE, 2008, 54 (03) : 259 - 264
  • [36] Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience
    Arledge, T
    Freeman, A
    Arbuckle, J
    Mosteller, M
    Manasco, P
    DRUG METABOLISM REVIEWS, 2000, 32 (3-4) : 387 - 394
  • [37] New applications of disease genetics and pharmacogenetics to drug development
    Roses, Allen D.
    Saunders, Ann M.
    Lutz, Michael W.
    Zhang, Nanyin
    Hariri, Ahmad R.
    Asin, Karen E.
    Crenshaw, Donna G.
    Budur, Kumar
    Burns, Daniel K.
    Brannan, Stephen K.
    CURRENT OPINION IN PHARMACOLOGY, 2014, 14 : 81 - 89
  • [38] Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
    Mooij, Miriam G.
    Nies, Anne T.
    Knibbe, Catherijne A. J.
    Schaeffeler, Elke
    Tibboel, Dick
    Schwab, Matthias
    de Wildt, Saskia N.
    CLINICAL PHARMACOKINETICS, 2016, 55 (05) : 507 - 524
  • [39] Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA-PWG-PhRMA-DruSafe workshop
    Lesko, LJ
    Salerno, RA
    Spear, BB
    Anderson, DC
    Anderson, T
    Brazell, C
    Collins, J
    Dorner, A
    Essayan, D
    Gomez-Mancilla, B
    Hackett, J
    Huang, SM
    Ide, S
    Killinger, J
    Leighton, J
    Mansfield, E
    Meyer, R
    Ryan, SG
    Schmith, V
    Shaw, P
    Sistare, F
    Watson, M
    Worobec, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04): : 342 - 358
  • [40] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
    Amur, Shashi
    Frueh, Felix W.
    Lesko, Lawrence J.
    Huang, Shiew-Mei
    BIOMARKERS IN MEDICINE, 2008, 2 (03) : 305 - 311
12345